

DAFTAR PUSTAKA

- Anonim, 2018, *The Global Asthma Report 2018*, New Zeland: Global Asthma Network, Aukland.
- Austin, R. P., Barton, P., Bonnert, R. V., Brown, R. C, Cage, P. A., Cheshire, D. R., Young, A., 2003, QSAR and the Rational Desaign of Long-Acting Dual D2-Receptor/ β 2-Adrenoreceptor Agonists, *Journal of Medicinal Chemistry*, 46(15), 3210-3220.
- Baur, F., Beattie, D., Beer, D., Bentley, D., Bradley, M., Bruce, I., ... Wyss, D., 2010, The Identification of Indacaterol as an Ultralong-Acting Inhaled β 2-Adrenoreceptor Agonist, *Journal of Medicinal Chemistry*, 53(9), 3675-3684.
- Billington, C. K., Penn, R. B., & Hall, I. P., 2016, β 2 Agonists, *Pharmacology and Therapeutics of Asthma and COPD*, 23-40.
- Cazzola, M., Calzetta, L., & Matera, M. G., 2011, β 2-adrenoreceptor agonist: current and future direction, *British Journal of Pharmacology*, 163(1), 4-17.
- Chung, K. F., 2017, Clinical management of severe therapy-resistant asthma, *Expert Review o Respiratory Medicine*, 1-8.
- Cichero, E., & Fossa, P., 2011, Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitor, *Journal of Molecular Modeling*, 18(4), 1573-1582.
- Dar, A.M. & Mir, S., 2017, molecular Docking: Approaches, Types, Applications and Basic Challenges, *J Anal Biotech*, 8(2)
- GINA, 2017, Mechanism of Asthma in Global Strategy for Asthma Management and Prevention 2017, <http://www.ginasthama.com>, 20 April 2019.
- Gini, G., 2016, QSAR Methods, *In Silico Methods for Predicting Drug Toxicity*, 1-20.
- Gini, G, 2018, QSAR: What Else? *Computation Toxicology*, 79-105.
- Hausdorff, W. P., Caron, M. G., & Lefkowitz, R. J., 1990, Turning off the signal: desensitization of beta-adrenergic receptor function, *The FASEB Journal*, 4(11), 2881-2889.

- Hong, H., Chen, M., Ng, H. W., & Tong, W, 2016, QSAR Model sat the US FDA/NCTR, *In Silico Methods for Predicting Drug Toxicity*, 431-459.
- Johnson, M., 2006, Molecular mechanisms of β 2-adrenergic receptor function, response, and regulation, *Journal of Allergy and Clinical Immunology*, 117(1), 18-24.
- Matera, M.G., Rinaldi, B., Calzetta, L., & Cazzola, M., 2016, Assessing the viability of long-acting β 2-agonists in paediatric asthma pasien: *a pharmacokinetic/pharmacodynamic perspective*, *Expert Opinion on Drug Metabolism & Toxicology*, 13(2), 129-136.
- Mathers, C. D., & Loncar, D., 2006, Projections of Global Mortality and Burden of Disease from 2002 to 2030, *PLoS Medicine*, 3(11), e442.
- Mims, J. W., 2015, Asthma: definitions and pathophysiology. *Internasional Forum of Allergy & Rhinology*, 5(S1), S2-S6.
- Strosberg, A. D., 1993, Structure, function, and regulation of adrenergic receptors, *Protein Science*, 2(8), 1198-1209.
- Susanti E., 2012, Desain Molekul Baru Inhibitor Enzim 5-Lipoksinase (5-LOX) Melalui Pendekatan QSAR (*Quantitative Structure Activity Relationship*), *Skripsi*, Fakultas Farmasi Universitas Gadjah Mada Yogyakarta.
- Vilar, S., & Costanzi, S, 2012, Predicting the Biological Activities Through QSAR Analysis and Docking-Based Scoring, *Membrane Protein Structure and Dynamics*, 271-284.
- Weichert, D., Stanek, M., Hubner, H., & Gmeiner, P., 2016, Structure-guided development of dual β 2 adrenergic/dopamine D2 receptor agonists, *Bioorganic & Medicinal Chemistry*, 24(12), 2641-2653.
- WHO, 2017, Chronic Respiratory Diseases, <https://www.who.int/respiratory/>, 20 April 2019.
- Young, D.C., 2001, *Computation Chemistry: Pratical Guide for Applying Techniques to Real-World Problem*, John Wiley & Sons, Inc., New York.